WCLC 2025 - Posters & ePosters-EP.12.47 Persistent Response of Sunvozertinib in Lung Adenocarcinoma Patient With EGFR Exon 20 Insertion Mutation

EP.12.47 Persistent Response of Sunvozertinib in Lung Adenocarcinoma Patient With EGFR Exon 20 Insertion Mutation

Pdf Summary

This report presents a case study of a 67-year-old male patient with advanced lung adenocarcinoma harboring an EGFR exon 20 insertion (p.P772delinsPH) mutation and high PD-L1 expression (80%). Initially diagnosed in February 2022 with extensive disease including lung tumor and metastases to lymph nodes, ribs, and vertebrae, the patient underwent multiple treatment lines.<br /><br />First, combination immunotherapy with tislelizumab plus chemotherapy (pemetrexed and carboplatin) from March to July 2022 achieved a partial response, though mild leukopenia occurred. Continued chemotherapy alone from July 2022 to February 2023 stabilized the disease, accompanied by mild adverse effects (leukopenia, fatigue, diarrhea). From February to December 2023, pemetrexed monotherapy maintained stable disease, with manageable side effects including grade 1 leukopenia and grade 2 phlebitis.<br /><br />Due to intolerance to prolonged intravenous therapies, treatment switched to oral sunvozertinib 300 mg daily (a potent, selective EGFR tyrosine kinase inhibitor approved in China for EGFR exon20ins-mutated NSCLC) starting December 2023. The patient experienced stable disease and only grade 1 diarrhea and paronychia as side effects. As of July 2025, progression-free survival had reached 40 months on sunvozertinib maintenance.<br /><br />This case demonstrates that sunvozertinib is a well-tolerated and effective first-line maintenance therapy option following immunotherapy and chemotherapy in lung adenocarcinoma patients with EGFR exon20 insertion mutations. The observed long-term disease control and favorable safety profile support further exploration of sunvozertinib in this setting. These findings align with previous clinical studies showing high response rates and tolerability of sunvozertinib in advanced NSCLC with EGFR exon20ins mutations.

Asset Subtitle

Hui Han

Meta Tag

Speaker Hui Han

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

lung adenocarcinoma

EGFR exon 20 insertion

p.P772delinsPH mutation

high PD-L1 expression

tislelizumab

pemetrexed

carboplatin

sunvozertinib

progression-free survival

EGFR tyrosine kinase inhibitor